Echo IQ Secures 6-Year Distribution Deal with World-Top Hospital

Key Highlights:

• Echo IQ signs expanded 6-year distribution deal with Mayo Clinic platform
• Access to 80+ hospitals and broader US healthcare network
• EchoSolv HF shows 99.5% sensitivity in heart failure detection
• Targets 16 million annual echocardiograms in the US
• Shares rise 15.45% as commercial pathway strengthens
  
   

In the world of healthcare technology, breakthroughs are often judged not just by science, but by who is willing to use them.

For Echo IQ, that validation has arrived in the form of a long-term commercial agreement with one of the most respected medical institutions globally, the Mayo Clinic.

The Australian med-tech company has secured an expanded six-year distribution deal that could fast-track its artificial intelligence tool into hospitals across the United States, pending regulatory approval.

Investors took notice. Shares in Echo IQ climbed 17.07% to $0.72, reflecting growing confidence that the company is moving beyond clinical promise toward real-world deployment.

From lab to hospital corridors

Echo IQ’s flagship product, EchoSolv HF, will be deployed through the Mayo Clinic Platform Solutions Studio Program, giving it access to Mayo hospitals, its health system network, and more than 80 partner hospitals across the US.

For a company of Echo IQ’s size, this solves one of the biggest challenges in healthcare innovation: distribution.

Instead of building a costly sales infrastructure from scratch, Echo IQ is effectively plugging into an existing ecosystem that already reaches thousands of clinicians and millions of patients.

Chief Executive Officer Dustin Haines described the milestone as transformational:

“The expansion of our agreement with Mayo Clinic is one of the more strategically important milestones in the Company’s history. A more equitable arrangement with one of the most respected hospital systems in the US, as we move closer to FDA clearance and commercial deployment, leaves us well positioned for the months ahead.”

A six-year runway to revenue

The revised agreement includes an initial three-year term with an automatic extension for another three years, creating a potential six-year commercial partnership.

More importantly, the company noted that the updated terms are “more equitable,” suggesting improved revenue sharing compared to the earlier 2025 arrangement.

In simple terms, Echo IQ has not just secured access to a large market. It has negotiated a better slice of the economics.

This shifts the company’s profile closer to a software-as-a-service healthcare model, where recurring usage across hospital networks can translate into predictable revenue streams over time.

The science behind the surge

While the commercial deal is the headline, the underlying technology is what makes it credible.

EchoSolv HF is designed to detect heart failure using echocardiogram data, an area where misdiagnosis remains a persistent problem.

A validation study conducted through the Mayo Clinic platform reported:

• 99.5% sensitivity, meaning the system almost never misses a true case of heart failure
• 91.1% specificity, indicating strong accuracy in ruling out false positives
  
   

In clinical terms, sensitivity is critical. Missing a heart failure diagnosis can lead to severe complications or death. A tool that consistently identifies these cases becomes not just useful, but essential.

Haines added:

“This milestone reflects the strength of the EchoSolv HF clinical utility and the growing commercial value of the solution, while the revised agreement provides a scalable pathway to market through the Mayo Clinic Platform.”

A massive market, still underdiagnosed

The opportunity Echo IQ is targeting is substantial.

According to company data:

• Around 6.7 million Americans currently live with heart failure
• An estimated 2 million cases remain undiagnosed
• Approximately 16 million echocardiograms are performed annually in the US
• Nearly 50% of these scans contain heart failure-relevant findings
  
   

This creates what analysts often call a “diagnostic gap.”

Despite advanced imaging technology, many cases are still missed or detected too late. Echo IQ’s software aims to sit inside existing workflows and flag these cases early, effectively acting as a second set of eyes for clinicians.

From a commercial standpoint, even a small per-scan fee applied across millions of tests could translate into significant revenue potential.

Industry context: AI meets cardiology

Echo IQ’s move comes at a time when artificial intelligence is rapidly gaining traction in healthcare.

Hospitals are increasingly adopting AI tools to improve diagnostic accuracy, reduce workload pressures, and manage rising patient volumes.

However, adoption has been uneven. Many technologies struggle to move beyond pilot programs due to integration challenges or lack of clinical validation.

This is where partnerships like the Mayo Clinic deal matter.

The Mayo Clinic is widely regarded as a global leader in cardiology and clinical research. Its endorsement provides a level of credibility that few institutions can match.

Historically, similar partnerships have acted as launchpads for broader adoption, particularly in the US healthcare system where trust and validation play a central role.

The regulatory hurdle still ahead

Despite the optimism, one key step remains.

EchoSolv HF has not yet received clearance from the US Food and Drug Administration. The company has submitted its application through the 510(k) pathway and is currently awaiting a decision.

Until that approval is granted, the product cannot be commercially deployed in the US.

Echo IQ acknowledges this clearly, noting that all distribution and revenue opportunities are contingent on regulatory clearance.

Still, the company appears confident.

Haines said:

“While our application with the FDA is still under review, we continue to remain confident in our submission. Our focus is on preparing for rapid commercial rollout, expanding our network of US healthcare partners, and positioning EchoSolv as a standard decision support tool within cardiac imaging workflows.”

Market perspective: from potential to pathway

What makes this development significant is not just the partnership itself, but what it represents.

Many early-stage med-tech companies struggle to bridge the gap between clinical validation and commercial adoption. Echo IQ has effectively built that bridge before the final regulatory step is complete.

The infrastructure is in place. The partner is secured. The market need is well defined.

What remains is the regulatory green light.

In a sector where timing, trust, and scalability are everything, Echo IQ has aligned all three.

If approval comes through, the company will not be starting from scratch. It will be stepping into a ready-made distribution engine, already connected to one of the most trusted names in global medicine.